article
Precision medicine: exploring the impact of DNA Testing
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.
List view / Grid view
Personalised Medicine
article
Navigating the challenges and opportunities of AI in drug development and personalised medicine
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
news
Revolutionary way to measure proteins aids precision medicine advancements
Using a nanofluidic aptamer nanoarray to measure biomolecules including proteins, Japanese researchers are attempting to bridge the gap for precision medicine
webinar
Innovations in organoid modelling for disease modelling and cell therapy
14 June 2023 | By Sartorius
Watch our virtual panel, where you'll uncover the game-changing advantages of organoids over traditional 2D cultures. Our experts will explore the immense potential of organoids in oncology and immuno-oncology research.
article
Challenges and promises of personalised precision medicine
Drug Target Review’s Taylor Mixides exclusively interviews Neil Thomas, Partner and Head of Healthcare and Life Sciences for EMEA at Infosys Consulting, on personalised precision medicine, its advances, challenges and the future.
news
Inflammation ‘brake’ gene may impact kidney disease outcomes
Australian researchers uncover a gene that controls inflammation in kidney disease, which could pave the way for more precise disease diagnostics and personalised treatments.
article
2023 drug discovery forecast: emerging trends and disruptors revolutionising the industry
With advancements in artificial intelligence, precision medicine and gene editing, the field of drug discovery is undergoing a rapid transformation. In this article, Drug Target Review’s Izzy Wood gets the insider knowledge from industry leaders at SLAS 2023, who are experiencing these changes first hand.
news
Assessing the accuracy of model arteries
Japanese scientists have tested the material used to build models of arteries, revealing their suitability for use in medical education and surgical planning.
news
Researchers develop organoid models to study non-alcoholic fatty liver disease
The team used these models to show drug responses and established a CRISPR-screening platform to identify potential therapeutic targets for non-alcoholic fatty liver disease.
whitepaper
Whitepaper: Organoids: How close are we to the clinic?
Explore current insights into the clinical possibilities posed by organoids and delve into short and long-term prospects for therapeutic screening and personalised regenerative medicine in this whitepaper.
whitepaper
Glossary: Multiplexing 101 – The essential guide
What is multiplexed immunofluorescence microscopy imaging?
whitepaper
Article: Understanding potency in cell and gene therapy development
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
whitepaper
Article: Challenges in developing CAR T-cell therapies
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
webinar
Translating complex, high-parameter immune data from clinical samples into actionable disease insights
1 November 2022 | By Standard BioTools
Watch our on-demand webinar to hear about advances toward precision medicine through the use of cutting-edge methods and analysing critical patient immune data in response to therapies and disease progression.
webinar
Power up your LNP and AAV sample prep with Unagi
12 October 2022 | By Unchained Labs
Watch this on-demand webinar to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs.